vs
Side-by-side financial comparison of Angel Oak Mortgage REIT, Inc. (AOMR) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.
Angel Oak Mortgage REIT, Inc. is the larger business by last-quarter revenue ($10.9M vs $8.4M, roughly 1.3× Immunovant, Inc.). Angel Oak Mortgage REIT, Inc. runs the higher net margin — 103.9% vs -899.0%, a 1002.9% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 10.4%).
Angel Oak Mortgage REIT, Inc. is a U.S.-based real estate investment trust focused on investing in residential mortgage assets, including non-agency mortgage-backed securities, residential mortgage loans, and credit-linked real estate instruments. It serves U.S. institutional and retail investors, targeting competitive risk-adjusted returns through regular income and long-term capital growth.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.
AOMR vs IMVT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $10.9M | $8.4M |
| Net Profit | $11.3M | $-75.3M |
| Gross Margin | — | — |
| Operating Margin | — | -896.2% |
| Net Margin | 103.9% | -899.0% |
| Revenue YoY | 10.4% | 140.7% |
| Net Profit YoY | 175.2% | -26.7% |
| EPS (diluted) | $0.44 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.9M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $10.1M | — | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $8.6M | $8.4M |
| Q4 25 | $11.3M | — | ||
| Q3 25 | $11.4M | — | ||
| Q2 25 | $767.0K | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | $-15.1M | — | ||
| Q3 24 | $31.2M | — | ||
| Q2 24 | $-273.0K | — | ||
| Q1 24 | $12.9M | $-75.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -152.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | — | -896.2% |
| Q4 25 | 103.9% | — | ||
| Q3 25 | 112.1% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 203.5% | — | ||
| Q4 24 | -152.6% | — | ||
| Q3 24 | 345.9% | — | ||
| Q2 24 | -2.9% | — | ||
| Q1 24 | 150.1% | -899.0% |
| Q4 25 | $0.44 | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $0.87 | — | ||
| Q4 24 | $-0.62 | — | ||
| Q3 24 | $1.29 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $0.51 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.6M | $635.4M |
| Total DebtLower is stronger | $2.3B | — |
| Stockholders' EquityBook value | $267.5M | $617.8M |
| Total Assets | $2.7B | $666.4M |
| Debt / EquityLower = less leverage | 8.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.6M | — | ||
| Q3 25 | $51.6M | — | ||
| Q2 25 | $40.5M | — | ||
| Q1 25 | $38.7M | — | ||
| Q4 24 | $40.8M | — | ||
| Q3 24 | $42.1M | — | ||
| Q2 24 | $44.0M | — | ||
| Q1 24 | $39.4M | $635.4M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $267.5M | — | ||
| Q3 25 | $264.2M | — | ||
| Q2 25 | $246.4M | — | ||
| Q1 25 | $251.5M | — | ||
| Q4 24 | $239.0M | — | ||
| Q3 24 | $265.1M | — | ||
| Q2 24 | $255.8M | — | ||
| Q1 24 | $263.3M | $617.8M |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.3B | $666.4M |
| Q4 25 | 8.51× | — | ||
| Q3 25 | 8.37× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-407.0M | $-59.7M |
| Free Cash FlowOCF − Capex | — | $-59.8M |
| FCF MarginFCF / Revenue | — | -714.4% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | -35.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-214.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-407.0M | — | ||
| Q3 25 | $-173.4M | — | ||
| Q2 25 | $20.6M | — | ||
| Q1 25 | $-201.7M | — | ||
| Q4 24 | $-221.5M | — | ||
| Q3 24 | $-212.4M | — | ||
| Q2 24 | $-24.2M | — | ||
| Q1 24 | $40.2M | $-59.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-59.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -714.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.8% |
| Q4 25 | -35.96× | — | ||
| Q3 25 | -15.19× | — | ||
| Q2 25 | 26.92× | — | ||
| Q1 25 | -9.83× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AOMR
| Nonrelated Party | $6.4M | 59% |
| Other | $4.5M | 41% |
IMVT
Segment breakdown not available.
